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Available online 18 February 2013Abstract Cell replacement is an emerging therapy for type 1 diabetes. Pluripotent stem cells have received a lot of attention as a
potential source of transplantableβ-cells, but their ability to form teratomas poses significant risks. Here, we evaluated the potential
of primary mouse gall bladder epithelial cells (GBCs) as targets for ex vivo genetic reprogramming to the β-cell fate. Conditions for
robust expansion and genetic transduction of primary GBCs by adenoviral vectors were developed. Using a GFP reporter for insulin,
conditions for reprogramming were then optimized. Global expression analysis by RNA-sequencing was used to quantitatively
compare reprogrammed GBCs (rGBCs) to true β-cells, revealing both similarities and differences. Adenoviral-mediated expression of
NEUROG3, Pdx1, andMafA in GBCs resulted in robust induction of pancreatic endocrine genes, including Ins1, Ins2, Neurod1, Nkx2-2
and Isl1. Furthermore, expression of GBC-specific genes was repressed, including Sox17 andHes1. Reprogramming was also enhanced
by addition of retinoic acid and inhibition of Notch signaling. Importantly, rGBCs were able to engraft long term in vivo and remained
insulin-positive for 15 weeks. We conclude that GBCs are a viable source for autologous cell replacement in diabetes, but that
complete reprogramming will require further manipulations.
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The initial success of the Edmonton protocol highlighted the
potential of cell replacement therapy in type 1 diabetes
(Shapiro et al., 2000). However, wider application of this
approach is severely limited by the shortage of transplantable
pancreatic β-cells (de Kort et al., 2011). In addition, the
transplantation of cadaveric islets requires life-long immune
suppression (Ricordi and Strom, 2004). Ideally, therefore, a
source of transplantable β-cells would be both autologous and
abundant. Because of their in vitro growth capacity, plurip-
otent stem cells (PSCs) are an attractive potential source of
transplantable β-cells. While significant progress has been
made, the generation of true β-cells in vitro has remained
elusive thus far (Alipio et al., 2010; D'Amour et al., 2006;
Nostro et al., 2011). In addition, PSCs are capable of forming
teratomas and represent an unknown risk in terms of
tumorigenesis (Fujikawa et al., 2005; Kroon et al., 2008).
Direct genetic reprogramming of postnatal primary cells by
forced expression of key developmental transcription factors
has emerged as an alternative to in vitro differentiation of
PSCs. This strategy has been used successfully to produce
functional cells, including neurons, hepatocyte-like cells
and cardiomyocytes from fibroblasts (Huang et al., 2011; Ieda
et al., 2010; Vierbuchen et al., 2010). Similarly, in vivo
reprogramming of hepatic cells by expressing different pancre-
atic transcription factors, including Neurog3 and Pdx1, was
able to restore euglycemia in hyperglycemic mice (Ferber
et al., 2000; Wang et al., 2007; Vijay Yechoor et al., 2009).
Additionally, in vivo reprogramming of exocrine acinar cells
into insulin-positive cells by expression of Neurog3, Pdx1 and
MafA was also able to reverse hyperglycemia in mice (Zhou
et al., 2008). Furthermore, overexpression of Neurog3 and
Pdx1 has been shown to enhance pancreatic differentiation
of embryonic stem cells (Kubo et al., 2011). Other cell types
have also been tested for amenability to reprogramming
towards the β-cell fate, including adipose tissue-derived stem
cells, placenta-derived multipotent stem cells, hepatocytes,
intrahepatic biliary epithelial cells and gall bladder cells
(Chandra et al., 2011; Chiou et al., 2011; Coad et al., 2009;
Motoyama et al., 2009; Nagaya et al., 2009; Shigeru et al.,
2007).
The extrahepatic biliary tissue, including the gallbladder, is
a particularly appealing source of cells for reprogramming to
the pancreatic fate. The extrahepatobiliary system shares a
common developmental origin with the ventral pancreas, from
a cell termed the pancreatobiliary progenitor (Spence et al.,
2009). Segregation of these distinct lineages is partly regulated
by the Notch effector Hes1. Recently it was demonstrated that
inhibition of Hes1 in cultured gall bladder cells (GBCs) was
sufficient to induce some insulin expression (Coad et al., 2009).
While this work highlighted the potential of GBCs as a source of
transplantable β-cells, the full spectrum of β-cell expressed
genes or the in vivo functionality of these cells was not
determined. Moreover, the cells showed only limited prolifer-
ative potential under the culture conditions used. For GBCs to
be a viable substrate of future β-cell replacement therapies,
they would have to be robustly expandable (Yechoor and Chan,
2010). Therefore, the true utility of GBCs as a source of
transplantable β-cells remains unknown.
In this study, we investigated if mouse GBCs significantly
expanded in vitro can still be reprogrammed towards theβ-cell fate by using a combination of positive instructive
signals as well as Notch inhibition. GBCs were transduced
with adenoviruses expressing the transcription factors
NEUROG3, Pdx1 and MafA and treated with retinoic acid
and Notch inhibitors, resulting in their differentiation into
islet-like cells. Reprogrammed cells had the ability to
engraft, survive and remain insulin-positive up to 15 weeks
post-transplantation. However, there were also differences
between the reprogrammed GBCs and true β-cells. Our
findings confirm that the gall bladder represents a promising
source of autologous reprogrammable cells for the treat-
ment of type 1 diabetes mellitus.
Materials & methods
Mouse gall bladder cell isolation and culture
Gall bladders from C57Bl6/6J-MIP-GFP male and female mice
between the ages of 4 and 8 weeks were removed by a surgical
incision and bile released by making a single cut in the wall.
Gall bladders were rinsed twice in DPBS (Life Technologies,
Grand Island, Ca) and then cut into several pieces. This
material was then incubated at 37 °C with 0.25% Trypsin/
EDTA (Life Technologies, Grand Island, Ca) for 45 min to
obtain a cell suspension. Cells were cultured using a modified
protocol to that previously described (Manohar et al., 2011).
Briefly, cells were plated on a 70–80% confluent irradiated
LA7 rat epithelial feeder layer that had been previously
irradiated at 60 Gy. Cells were cultured in DMEM/F12 (Life
Technologies, Grand Island, Ca) supplemented with 0.5% FBS
(Thermo Fisher Scientific, Cambridge, MA), 1% insulin–
transferrin–selenium (Roche, Indianapolis, IN), 15 mM HEPES
(Thermo Fisher Scientific, Cambridge, MA) and antimicrobials
(100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml
Amphotericin B; Cellgro, Manassas, VA) in a 37 °C incubator
with 5% CO2. Media was changed every two to three days.
When GBCs were 70–90% confluent, they were passaged by
incubation with 0.05% trypsin/EDTA (Life Technologies, Grand
Island, Ca) at 37 °C, followed by incubation with DNaseI at
37 °C for 10 min to obtain a single cell suspension.
Fibroblast culture
For initiating fibroblast cultures, mouse tail-tips from eutha-
nized C57Bl6/6J-MIP-GFP mice were washed with DPBS, cut
into several pieces, and digested with 0.25% Trypsin/EDTA for
60 min at 37 °C with regular mixing. Upon inactivation of
trypsin by addition of serum, the tissue mix was spun at
1000 rpm for 5 min, resuspended in DMEM supplemented with
15% FBS and antimicrobials, followed by plating in a 37 °C
incubator with 5% CO2. Media was changed every two to three
days.
Adenovirus transduction of GBCs
Each E1-deleted adenovirus (serotype 5) consisted of the
full-length cDNA (human NEUROG, rat Pdx1, mouse MafA;
NEUROG3 and Pdx1 provided by Michael German, University
of California at San Francisco; MafA provided by Roland
Stein, Vanderbilt University Medical Center) driven by the
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was expanded in HEK293 cells and purified using the
FastTrap Purification Kit (Millipore, Billerica, MA) per the
manufacturer's protocol. Adenovirus titers were calculated
based on spectrometry. Adenoviruses expressing NEUROG3
(MOI 1000), Pdx1 (MOI 500), and MafA (MOI 500) were
incubated in 100 μg/ml DEAE-Dextran (Sigma-Aldrich, St.
Louis, MO) for 30 min at room temperature with regular mixing
prior to addition to the cell media for a final concentration of
10 μg/ml DEAE-Dextran. Media was changed 20–24 h post
transduction.GBC reprogramming
GBC cultures were grown to ~70% confluency. On this day,
day 0, cells were transduced with the adenovirus/DEAE-
Dextran mix. 20–24 h later, the media was changed to
include 2 μM retinoic acid (Sigma-Aldrich, St. Louis, MO) and
1% DMSO (Thermo Fisher Scientific, Cambridge, MA). Twenty
four hours later, the media was changed to include 250 nM
of the γ-secretase inhibitor dibenzazepine (DBZ; EMD
Chemicals, Darmstadt, Germany) and 1% DMSO. All cells,
attached and in suspension, were kept by spinning the media
to pellet all cells prior to addition of new media.Flow cytometry and FACS
For antibody labeling, GBCs were dissociated into single cells
using a non-trypsin method (Cell dissociation buffer; Gibco,
Grand Island, CA). Dissociated cells were resuspended in
DMEM, supplemented with 2% FBS and 0.25 mg/ml DNaseI
(Sigma-Aldrich, St. Louis, MO). Propidium iodide staining
was used to label dead cells for exclusion. The forward
scatter (FSC):pulse width gating excluded cell doublets from
sorts, as previously described (Dorrell et al., 2008). Cells
were analyzed with a FACScalibur or sorted by an inFluxV-GS
(BD Biosciences, San Jose, CA for both) at 15 psi using a
100 μm nozzle. Data were analyzed using FlowJo (Treestar,
Ashland, OR).RNA isolation and qRT-PCR
For RNA isolation, cells were either directly FACS-sorted into
Trizol Liquid Sample (Life Technologies, Grand Island, CA) or
trypsinized and pelleted by centrifugation prior to cell lysis
with Trizol. RNA was purified using RNeasy (Qiagen,
Valencia, CA) per the manufacturer's protocol. First strand
cDNA synthesis was completed using MMLV reverse tran-
scriptase and random oligonucleotide primers (Life Technol-
ogies, Grand Island, CA). Relative mRNA expression levels
were determined by qRT-PCR using a BioRad iCycler with a
single color MyiQ detection system. All reactions were
performed with Platinum Taq DNA Polymerase (Life Tech-
nologies, Grand Island, CA) and SYBR Green using 45 cycles
of 95 °C for 15 s, 68 °C for 20 s, and 72 °C for 20 s. The full
list of mouse-specific primers is given in Table S4. Results
were analyzed using gene expression relative to control
Alas1 or Actb gene expression (ΔΔCT). qPCR data were
expressed as mean fold change (2ΔΔCT) ± 95% confidence.Immunohistochemistry and immunofluorescent
imaging
For cytospin imaging, either reprogrammed GFP+ cells or
non-adenovirus transduced control cells were spun at
1000 rpm for 5 min onto Superfrost Plus slides (Thermo
Fisher Scientific, Cambridge, MA). Cells were fixed in either
4% paraformaldehyde or 90% methanol at 4 °C for 10 min.
Prior to labeling, cells were blocked in 5% BSA for 60 min
at 23 °C. Primary labeling was performed overnight at 4 °C
in PBS supplemented with 2% BSA and 0.05% Triton-X
using rabbit polyclonal antibodies against insulin (H-86;
Santa Cruz Biotechnology, Santa Cruz, CA), C-peptide (BCBC
collection #1042), Neurod1 (16508; Abcam, Cambridge, MA)
and Somatostatin (A0566; DAKO, Carpinteria, CA). Second-
ary labeling was performed for 60 min at 23 °C in PBS
supplemented with 2% BSA and 0.05% Triton-X with a 1:200
dilution of Alexa 555-conjugated goat anti-rabbit IgG
(Cell Signaling, Danvers, MA). Nuclei were stained using
Hoechst 33342 (Sigma-Aldrich, St. Louis, MO). For IHC
analysis, formalin-fixed paraffin-embedded kidneys were
sectioned and labeled with a primary antibody against
insulin (H-86; Santa Cruz Biotechnology, Santa Cruz, CA)
and detected using previously described methods (Overturf
et al., 1996).Enzyme-linked immunosorbent assay
Control and rGBCs were harvested at the indicated time
points. Cells were washed twice in Krebs Ringer Buffer
supplemented with 2.8 mM glucose (KRB-2.8) and incubated
at 37 °C for 90 min in KRB. Following two further washes
in KRB-2.8, cells were incubated in either KRB-2.8 or
Krebs Ringer Buffer supplemented with 16.7 mM glucose
(KRB-16.7) for 60 min at 37 °C. Cells were spun at 1200 rpm
for 5 min and the media collected and stored at −80 °C.
Insulin quantitative analyses were performed as per the
manufacturer's instructions (Insulin Ultrasensitive ELISA,
Alpco, Salem, NH).Cell transplantation
GBCswere expanded to 70% confluency prior to reprogramming
at the indicated passage number (Table S3). Cells were
transduced with the three adenoviruses expressing NEUROG3,
Pdx1 and MafA with or without retinoic acid as described
in Table S1. One to three days later, cells were harvested
and shipped on ice to the University of Massachusetts Medical
School (Worcester, MA) for transplantation on the following
day. Cell viability was determined by propidium iodide staining
after shipping and prior to transplantation. 20 × 106 unsorted
cells were transplanted under the renal capsule of diabetic
NOD.Cg-Rag1tm1Mom IL2rgtm1WjlIns2Akita (NRG-Akita) and
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ Ins2Akita (NSG-Akita) mice, as
previously described (Brehm et al., 2010). Non-fasting blood
glucose levels were monitored following transplantation by
blood glucose measurements with an ACCUCHEK active
glucometer (Hoffman-LaRoche, Basel, Switzerland). The Insti-
tutional Animal Care and Use Committee approved all animal
studies.
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Libraries were single-read sequenced to 100 bp on an
Illumina hiSeq2000. Reads coming from ribosomal RNA and
repeats were filtered out by aligning 50 bp of all reads to
mouse ribosomal sequence and the human contents of
Repbase (release 14.10) (Jurka et al., 2005). The remaining
reads where processed with RUM (Grant et al., 2011) using
the default parameters to align reads to genome (mm9) and
gene models and to produce transcript-level quantification
in reads. Expression levels (in reads) were log2 transformed
and then normalized using quantile normalization (R limma).
After unclogging, data were converted to reads and
averaged between replicates. Differential expression was
determined using the Fisher exact test and Benjamini–
Hochberg correction for multiple testing on genes with at
least a two-fold difference between conditions. Gene lists
from either the up- or down-regulated portion of each
comparison were analyzed using Ingenuity Core Analysis
(Ingenuity Systems, www.ingenuity.com). The RNA-Seq data
was submitted to the European Bioinformatics Institute
ArrayExpress (http://www.ebi.ac.uk/arrayexpress/).Statistical analysis
Statistical analyses were conducted with GraphPad Prism
software v.4.0 or Microsoft Excel. Experimental differences
were evaluated by student two-tailed t-test assuming equal
variance. P values b 0.05 were considered statistically
significant.Results
Expansion and transduction of mouse gall bladder
cells
Cell replacement therapy for type 1 diabetes requires large
numbers of functional cells. Therefore, the expandability of
primary GBCs had to be demonstrated in order for the adult
gall bladder to be a viable alternative to pluripotent stem
cells (PSCs), which can be readily grown in vitro. A modified
protocol first reported by Manohar et al. was used to isolate
and expand mouse GBCs (Manohar et al., 2011). GBCs were
cultured on a feeder layer of irradiated LA7 rat epithelial
cells (Dulbecco et al., 1979) that allowed their robust
expansion. Upon initial harvest a typical mouse gall bladder
yielded approximately 200–400,000 cells that showed
unlimited ability to replicate and expand, normally gener-
ating hundreds of millions of cells by passage 3 (Figs. 1A–C).
Expanded cells also maintained their epithelial characteris-
tics and there was no evidence of epithelial–mesenchymal
transition based on expression of known mesenchymal
markers (Kalluri and Weinberg, 2009), including Acta2,
Col1a1, Ddr2, S100a4 and Vim (Table S1). Next, the
suitability of adenoviral vectors for the introduction of
transgenes in expanded GBCs was assessed. Less than 10% of
the cells were positive for the marker transgene GFP
when using standard transduction protocols (Figs. 1D, E).
DEAE-dextran has previously been shown to enhance the
transduction of other epithelial cells by adenoviral vectors(Gregory et al., 2003; Kaplan et al., 1998). Concentrations
greater than 10 μg/ml allowed transduction of more than
50% of the GBCs (Figs. 1D, F). Although higher concentra-
tions of DEAE-Dextran gave even greater transduction
efficiencies, they were also associated with increased
cell mortality (data not shown). Therefore, for all the
reprogramming experiments, a final DEAE-Dextran concen-
tration of 10 μg/ml was used for adenovirus transduction of
GBCs.
NEUROG3, Pdx1 and MafA are required for optimal
expression of both Ins1 and Ins2
In order to determine the optimal combination of
reprogramming transcription factors, a mouse reporter
strain (MIP-GFP Hara et al., 2003) in which the mouse Ins1
promoter drives expression of GFP was utilized. Multiple
pancreatic developmental transcription factors were tested
singly and in combinations, including Pdx1 (Jonsson et al.,
1994), NEUROG3 (Apelqvist et al., 1999), MafA (Nishimura et
al., 2006), and Nkx6-1 (Sander et al., 2000). In control GBCs,
no GFP expression was detected, indicating absence of
transcriptional activity from the Ins1 promoter (Fig. 2).
Previous work has shown that forced expression of Neurog3
or Pdx1 is sufficient to differentiate liver cells towards a
pancreatic fate in vivo (Ferber et al., 2000; Wang et al.,
2007). Although expression of these two factors together
induced low levels of GFP expression, adenoviral-mediated
expression of MafA, together with NEUROG3 and Pdx1, was
required for optimal GFP expression in GBCs in vitro
(Fig. 2A). Additional transduction of GBCs with Nkx 6-1 as a
fourth factor did not yield increased reprogramming (data
not shown). A second reporter strain was also generated by
breeding a mouse expressing Cre recombinase under control
of the rat Ins2 promoter with a dual reporter Tomato-RFP/
GFP mouse in which expression of GFP is only detected in
cells in which a Cre-mediated recombination event has
occurred (Muzumdar et al., 2007; Postic et al., 1999).
Control cultured GBCs were always GFP negative, whereas
GBCs reprogrammed with NEUROG3, Pdx1 and MafA (NPM)
activated the Ins2 promoter (Fig. S1). These results
indicated that both insulin promoters were active in
reprogrammed cells. For all subsequent experiments, GBCs
expanded from MIP-GFP mice (Ins1 promoter) were used.
Retinoic acid and Notch inhibition enhance
reprogramming of GBCs
Small molecules have previously been successively used for
reprogramming PSCs towards a pancreatic lineage (Kroon et
al., 2008; Nostro et al., 2011). The effect of retinoic acid
(RA) on reprogramming was first tested. By including RA in
the reprogramming media at a concentration of 2 μM, there
was a significant 2.2 fold increase in the percentage of GFP+
GBCs reprogrammed with NEUROG3, Pdx1 and MafA (NPM),
compared to GBCs reprogrammed with NPM alone (Fig. 2A).
The effect of inhibiting Notch signaling by using the gamma
secretase inhibitor dibenzazepine (DBZ) was examined next
(van Es et al., 2005). Inhibition of Notch signaling at day 2 of
reprogramming caused a further significant increase in GFP+
reprogrammed cells (Fig. 2A). RA or DBZ in the absence of
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Figure 1 Expansion and adenovirus transduction of GBCs. (A, B) Phase contrast images of passage 0 (A) and passage 3 (B) typical
GBC colonies. (C) GBCs were robustly expanded, generating hundreds of millions of cells by passage 3 (P3). The data shown is for two
independent gall bladders. (D) Without any DEAE-Dextran, only ~5% of cells were transduced by adenovirus expressing GFP at 500
MOI. However, with increasing concentrations of DEAE-Dextran, there was a significant increase in the number of GBCs transduced
(*p b 0.05; N = 3). (E, F) Fluorescent images showing (E) few GBCs GFP+ without DEAE-Dextran addition, whereas at 10 μg/ml (F),
~70% of the GBCs were GFP+. Scale bar for all images is 400 μm.
507Generation of islet-like cells from mouse gall bladder by direct ex vivo reprogrammingNPM did not cause any GFP+ cells to appear. The optimized
reprogramming timeline is shown in Fig. S2 and a represen-
tative FACS plot of GFP expression after reprogramming is
shown in Fig. 2B. As the cells were reprogrammed towards
the pancreatic fate, the morphology of the cells changed
and the GBCs lost their distinctive tight colony structure,
eventually loosing adherence and floating in suspension in
the culture. We next analyzed the expression of GFP over a
period of 12 days after reprogramming in two different gall
bladder samples (Fig. S3). The first GFP+ cells appeared
within 48 h after reprogramming was begun, with the
maximum number of GFP+ cells detected 24 h later. After
this time, the percentage of GFP+ cells decreased,coinciding with increased cell death under the culture
conditions used (data not shown).GBCs are rapidly reprogrammed towards the
β-cell-fate
Four days after reprogramming, reprogrammed GFP+ GBCs
were analyzed by flow cytometry and FACS-sorted for RNA and
protein analyses. Adenovirus GFP-only transduced GBCs were
used as the control. Using RNA-Seq, true reprogramming of
these GBCs was evident by induction of genes involved
in several aspects of β-cell function (Table 1) including
**
*
control “reprogrammed”B
G
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0 20.5
A
Figure 2 Optimization of GBC reprogramming. (A) Comparison of the percentage of GFP (=insulin1) expressing GBCs after
reprogramming. GFP+ percentage after reprogramming with the three transcription factors — NEUROG3, Pdx1 and MafA (NPM) was
arbitrarily set to 1. The combination of all three factors yielded significantly higher reprogramming rates compared to any combination of
two factors (*p b 0.05; N = 3). RA increased the percentage of GFP+ GBCs in cultures by approximately 2.2 fold (*p b 0.05; N = 3).
Addition of DBZ to the reprogramming mix on day 2 also increased the number of GFP+ GBCs. Addition of RA or GSI alone had no effect on
reprogramming. (B) GBCs from MIP-GFP mice were GFP-negative by flow cytometry, indicating no activity of the Ins1 promoter. Three
days after reprogramming, 20.5% of total GBCs in the plate became GFP+ using the optimized protocol depicted in Fig. S2.
508 R.D. Hickey et al.proinsulin production (Ins1, Ins2), insulin processing (Pcsk1,
Pcsk2, Cpe), transcription factors (Nkx2-2, Neurod1, Isl1),
glucose metabolism (Gck), ATP-sensitive K+ channels (Kcnj11),
calcium channels (Cacna1a) and insulin secretion (Chga, Scg3).
RNA-Seq data was validated for several genes by qRT-PCR (Figs.
S4A, B). In accordance with the gene expression data, rGBCs
also expressed the proteins for insulin, c-peptide, and Neurod1
(Fig. 3). In fact, all GFP+ FACS-sorted cells were positive for
these three proteins, indicating that the MIP-GFP reporter
system was an excellent read-out for GBC-derived islet-like
cells (Fig. 3). These results clearly demonstrated the activation
of many genes specific for pancreatic β-cells. However,
complete reprogramming involves not only the activation of
desired genes, but also the silencing of genes specific for thecell type of origin.Within three days post reprogramming, GFP+
GBCs showed significant decreases in expression of several
genes that are normally expressed in this cell type (Table S2). In
addition, the pancreatobiliary transcription factors Sox17 and
Hes1, required for normal gall bladder development and
homeostasis, were also reduced. The RNA-Seq data for these
genes was also validated by PCR (Fig. S4B).The pancreatic endocrine phenotype of rGBCs is
polyhormonal and non-glucose-responsive
Pancreatic endocrine cells produced by in vitro differenti-
ation of PSCs are mostly polyhormonal (D'Amour et al., 2006;
Table 1 Expression levels of β-cell-related genes in rGBCs relative to control GBCs. FC, fold change.
Gene Transcript Description FC p value
Ins1 NM_008386 Insulin I 4837.3 4.9E−04
Ins2 NM_001185083 Insulin II 7082.3 5.5E–06
Pcsk1 NM_013628 Proprotein convertase subtilisin/kexin type 1 16.6 1.9E–01
Pcsk2 NM_008792 Proprotein convertase subtilisin/kexin type 2 687.4 8.6E–02
Cpe NM_013494 Carboxypeptidase E 11.0 5.2E–03
Nkx2-2 NM_010919 NK2 transcription factor related, locus 2 11,625.5 9.9E–04
Neurod1 NM_010894 Neurogenic differentiation 1 40,063.5 2.3E–04
Isl1 NM_021459 ISL1 transcription factor, LIM/homeodomain 2749.6 1.6E–03
Pdx1 NM_008814 Pancreatic and duodenal homeobox 1 8.5 7.1E–03
Gck NM_010292 Glucokinase 28.3 4.1E–02
Kcnj11 NM_010602 Potassium inwardly rectifying channel, subfamily J, member 11 10,333.2 3.1E–04
Cacna1a NM_007578 Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 24.7 1.5E–04
Slc2a2 NM_031197 Solute carrier family 2 (facilitated glucose transporter), member 2 60.5 5.1E–03
Chga NM_007693 Chromogranin A 2157.3 1.0E–03
Scg3 NM_001164790 Secretogranin III 52,681.2 1.7E–05
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reprogramming of GBCs resulted in the emergence of pancre-
atic cell types other than β-cells, qPCR analysis of mRNA
expression was done initially on non-FACS sorted cells.
In addition to insulin, other endocrine hormones were also
produced, including Sst, Ppy, and Ghrl gene transcripts
(Fig. S5A). Expression levels of the exocrine genes Cela2a
(chymotrypsin-like elastase family, member 2A), Cpa2 (pan-
creatic carboxypeptidase A2) and Prss1 (trypsin 1) were also
assessed (Fig. S5B). While Cela2a mRNA was not detected in
reprogrammed cells, and there was no significant increase in
Prss1 expression between control and transduced cells, there
was a significant increase in expression of Cpa2. However, the
overall expression of Cpa2 in rGBCs was less than 0.001% of that
detected in normal pancreas. In order to determine if rGBCs
were polyhormonal, insulin-positive GFP+ GBCs were immuno-
stained for somatostatin. Indicative of a polyhormonal pheno-
type, insulin-positive cells were also somatostatin positive
(Fig. S5C). RNA-Seq data from FACS-sorted MIP-GFP+ cells
confirmed that insulin-positive cells also expressed Sst at levels
greater than 20,000 higher than control GBCs (p b 0.01).
When PSCs are differentiated toward the pancreatic
endocrine fate in vitro they are often reported to be capable
of tonic insulin secretion, but do not display increased secretion
in response to glucose (Kubo et al., 2011; Nostro et al., 2011). In
order to determine whether reprogrammed GBCs are superior
to PSC derivatives in vitro, insulin secretion wasmeasured after
exposure to glucose. Similar to cells produced by in vitro
differentiation of PSCs, rGBCs were able to secrete insulin, as
detected using an insulin-specific ELISA (Fig. S6). However, the
amount of insulin detected was not significantly different after
stimulation with higher glucose concentrations. Hence, like
their PSC derived counterparts rGBCs also did not display GSIS,
at least at early time points after reprogramming.RNA-SEQ analysis revealed only partial
reprogramming into mature β-cells
Both in vitro differentiated PSCs and the genetically
reprogrammed GBCs described here display polyhormonalgene expression and lack of glucose responsiveness. Howev-
er, the molecular mechanism(s) underlying this imperfect
β-cell phenotype are currently unknown. In order to better
understand the key differences between rGBCs and true
β-cells and to uncover new targets for future reprogramming
strategies, we assessed the complete mRNA expression
profile of rGBCs. RNA-sequencing technology and bioinfor-
matics were utilized to compare the transcriptomes of
adenovirus GFP-only transduced control GBCs, NPM rGBCs
(without RA and DBZ), NPM-RA-GSI GBCs (with RA and DBZ)
and β-cells. The heatmap depicted in Fig. 4A illustrates that
while several groups of genes were expressed in similar
fashion between mature β-cells and rGBCs, others were not.
Differential expression analysis between control GBCs,
NPM-RA-GSI GBCs and β-cells yielded a large number of
differentially expressed genes as shown in Figs. 4B and C.
Approximately 1800 genes were up or down regulated with
reprogramming after four days. However, a further 3200 to
3400 genes remained differentially expressed between
β-cells and rGBCs. A functional analysis of the 1759 genes
that were up-regulated in rGBCs indicates that a statistically
significant portion was associated with ‘neuronal functions’,
e.g. ‘neurotransmission’ (p = 1.97E−6) and ‘morphology of
neurons’ (p = 1.7E–1). Since the development of the endo-
crine pancreas and nervous systems shares many common
factors (Atouf et al., 1997), this finding was consistent with
the induction of pancreatic endocrine development. Howev-
er the transcriptional signature of a more mature β-cell
phenotype was also observable in that the functions
‘quantity of carbohydrate’ (p = 1.8E–2; 73 genes) and
‘quantity of hormone’ (p = 3.8E–3; 69 genes) were present
in rGBCs. The most significant canonical pathway was ‘MODY
signaling’ (p = 3.0E–7; 11 genes). Targets of the transcrip-
tion factors Neurod1, Neurog3, Isl1, Pdx1, Nkx2-2, Pax6,
Minx1, and Mafa (p = 8.0E–4) were enriched in this set as
well. On the other hand, the most significant functions
among the down-regulated genes were related to prolifera-
tion, e.g., ‘carcinoma’ (p = 1.7E–12; 452 genes), ‘prolifer-
ation of cells’ (p = 6.8E–17; 363 genes), and ‘cell death’
(p = 8.3E–17; 431 genes). ‘Immune response’ function was
also down-regulated (p = 1.1E–8; 227 genes). Targets of the
Control GBCs
2°Ab only
Insulin
C
Neurod1
GFP+ GBCs
A B
C D
E F
G H
Peptide
Figure 3 Characterization of protein expression changes in reprogrammedGBCs. Control or GFP+GBCswere stainedwith 2°Ab only (A, B)
or with antibodies against insulin (C, D), C-peptide (E, F), or Neurod1 (G, H). Representative images are shown for each cell type.
510 R.D. Hickey et al.estrogen receptor (ER) (p = 1.0E–8) and transcription factor
Hnf4a (p = 2.0E–8) were enriched in this set as well. Despite
these signatures suggestive of pancreatic endocrine differ-
entiation, direct comparison of β-cells to rGBCs indicated
that many genes related to ‘glucose metabolism disorder’
(p = 8.2E–4; 204 genes) and ‘diabetes mellitus’ (p = 9.7E–3;
159 genes) were differentially expressed. These differences
are indicative of incomplete reprogramming.GBCs are more readily reprogrammed towards the
β-cell fate than fibroblasts
Skin fibroblasts are a cell type which is even more readily
available than GBCs. Others previously demonstrated that
fibroblasts can be differentiated into some functional cell typessuch as neurons, hepatocyte-like cells, and cardiomyocytes
(Huang et al., 2011; Ieda et al., 2010; Vierbuchen et al., 2010).
To determine whether skin cells may be a suitable substrate for
generating β-cells by reprogramming, tail tip adult mouse
fibroblasts from MIP-GFP mice were expanded and exposed to
the same reprogramming regimen as GBCs. Three days later,
these cells were FACS-sorted based on GFP expression and gene
expression analyzed by RT-PCR and qPCR (Figs. 5A–C).
Interestingly, expression of NPM also was able to induce
promoter activity at the Ins1 locus, as determined by GFP
expression and detection of Ins1 mRNA after three days
(Figs. 5A, B). However, other important β-cell transcripts such
as Ins2, Neurod1 and Nkx6-1 were significantly less induced in
GFP+ fibroblasts than in rGBCs (Fig. 5B). Moreover, other key
β-cell transcripts expressed in rGBCs, including Nkx2-2, Pax4
and Pcsk2, were not detected at all in GFP+ fibroblasts using
NPM-RA-GSI rGBCs v control GBCs
β-cells v NPM-RA-GSI rGBCs  
A B
C
1759
13679
1819
Increased
Equal
Decreased
3432
9803
3247 Increased
Equal
Decreased
Figure 4 RNA-Seq analysis of rGBCs. (A) Adenovirus GFP-only infected GBCs (controls A & B) were compared to GBCs reprogrammed
with either NPM only (NPM) or with NPM, RA and DBZ (NPM-RA-GSI). Actual pancreatic β-cells (β-cells A & B & C) were used as the
optimal target population. The cladogram above the heat-map indicated rGBCs formed an intermediate population of cells with
characteristics of both GBCs and β-cells. The number of genes differentially expressed between rGBCs and control GBCs (B) and
between β-cells and rGBCs (C) is depicted, showing, for example, that after reprogramming 1759 genes showed increased expression,
1819 genes showed decreased expression, and 13,679 genes were unchanged in rGBCs compared to control GBCs.
511Generation of islet-like cells from mouse gall bladder by direct ex vivo reprogrammingRT-PCR (Fig. 5C). Overall, these results indicated that
GBCs were clearly more responsive to pancreatic endocrine
reprogramming than fibroblasts.Transplanted reprogrammed cells can engraft,
survive and produce insulin in diabetic mice
Finally, as it has been demonstrated that in vitromaturation for
several months is needed to generate functional β-cells from
PSCs (D'Amour et al., 2006), it was tested whether transplan-
tation of in vitro differentiated rGBCs could reverse hypergly-
cemia in diabetic mice. GBCs reprogrammed with NPM and
incubatedwith orwithout RAwere harvested from culture after
two to three days and transplanted under the renal capsule of
diabetic NOD.Cg-Rag1tm1Mom IL2rgtm1WjlIns2Akita (NRG-Akita)
and NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ Ins2Akita (NSG-Akita) mice(Table S3). Blood glucose levels were monitored weekly. Of the
19 transplanted mice, only one mouse showed a temporary
reversal of hyperglycemia that was not sustained (experiment
PW0; Fig. S7). Between 8 and 15 weeks after transplantation,
all mice were euthanized and the kidneys analyzed by
immunohistochemistry by staining with an anti-insulin anti-
body. Interestingly, although the transplanted cells were
unable to permanently reverse the hyperglycemia in any of
the recipients, 8/19 of the mice had insulin-positive cells in the
graft region of the kidney (Figs. 6A, B) compared with the
absence of insulin positive cells detected in any of the control
transplanted GBCs (data not shown). To determine if
transplanted cells were still polyhormonal, grafts were stained
with an antibody against somatostatin (Fig. S8). Some
somatostatin-positive cells were also detected in these grafts,
but their number was fewer than for insulin-positive cells in the
same mice.
CB
control “reprogrammed”A
G
FP
PI
0 5.5
Figure 5 Attempted reprogramming of fibroblasts to the β-cell fate. (A) By flow cytometric analysis, control MIP-GFP fibroblasts
did not contain any GFP+ cells. Adenovirus-NPM-transduced fibroblasts contained 5.5% GFP+ cells three days after reprogramming.
(B) FACS-sorted GFP+ fibroblasts expressed Ins1 mRNA by qPCR. The other β-cell-markers Ins2, Neurod1, and Nkx6-1 were expressed
at significantly lower levels in GFP+ fibroblasts compared to GFP+ rGBCs (normalized to Alas1) (p b 0.01; N = 3 replicates for each
sample; error bars represent the standard deviation). (C) Using RT-PCR analysis, fibroblasts transduced with NPM (Fibs+) did not
express Nkx2-2, Pax4 or Pcsk2 in contrast to GBCs transduced with NPM (GBC+). Actb and Gapdh were used as the housekeeping
loading controls.
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The results presented here establish a combined genetic and
small molecule approach to differentiate mouse GBCs towards
the pancreatic β-cell lineage (summarized in Fig. S2). The
expression of key transcription factors has been shown to be a
powerful method to directly reprogram one cell type
to another, without the need to go through a pluripotent
intermediate (Huang et al., 2011; Ieda et al., 2010;
Vierbuchen et al., 2010; Xie et al., 2004). It is interesting
that the three transcription factors capable of reprogramming
GBCs into islet-like cells are the same as those required for in
vivo reprogramming of the exocrine pancreas into endocrine
pancreas (Zhou et al., 2008), as well as in vitro reprogramming
of pancreatic exocrine cells into β-like cells (Akinci et al.,
2012). Therefore, together these results implicate Neurog3,
Pdx1 and MafA as the key genetic reprogramming factors
needed for the de novo generation of mouse β-cells. In
addition to expressing these three transcription factors, the
frequency of GFP+ rGBCs was augmented by the timedaddition of RA and DBZ, a Notch signaling effector. Both
these pathways are essential for normal pancreatic develop-
ment (Apelqvist et al., 1999; Martin et al., 2005; Stafford and
Prince, 2002). Manipulation of these pathways has also been
used to differentiate pluripotent stem cells towards a
differentiated β-cell fate, indicating manipulation of both
RA-responsive genes and Notch signaling to also be critical for
de novo β-cell differentiation (Kroon et al., 2008; Nostro
et al., 2011).
Moreover, Notch signaling, particularly involving Hes1, has
been implicated as a key regulator of cell fate choice during
differentiation of the pancreatobiliary progenitor (Spence
et al., 2009). In accordance with a shift towards pancreatic
differentiation of rGBCs, there was a significant decrease in
expression ofHes1, supporting a previous study that has shown
down-regulation of Hes1 to be a critical step in differentiation
of insulin-positive cells from extrahepatobiliary tissues (Coad
et al., 2009). The results presented here further strengthen
the case for using GBCs in β-cell reprogramming and expand
the previous observations. Firstly, our rGBCs consistently
AB
Figure 6 Immunohistochemistry of transplanted rGBCs. (A, B)
Insulin-positive cells (examples marked with black arrows) were
detected in 8/19 of the grafts and never in the adjacent kidney.
Two representative images are shown here. Scale bars are
100 μm.
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results of Coad and colleagues (Coad et al., 2009). Moreover,
induction of additional key β-cell transcription factors not
described in the Coad study, including Neurod1, Nkx2-2 and
Isl1, was observed here. Additionally, the ability to expand
GBCs significantly, while retaining their reprogrammability,
was not part of the earlier work.
One of the interesting features of the results presented
here is the rapid fate conversion of GBCs into insulin-positive,
islet-like cells. Within only 96 h of genetic manipulation by
transduction with NPM, de-repression of the insulin loci
occurred as evidenced by expression of GFP and detection of
both Ins1 and Ins2 mRNA. Other gene expression changes also
indicated that these cells were differentiating towards the
β-cell lineage, including increased expression of the tran-
scription factors Neurod1, Nkx2-2, Pax4, and Isl1. In addition,
rGBCs increased expression of the proprotein convertases
Pcsk1 and Pcsk2 which are needed to process the immature
proinsulin into insulin and c-peptide. In line with these gene
expression changes, processed insulin could be detected
by immunocytochemistry and by ELISA in rGBCs. The rapidchanges in the gene expression profiles are similar to those
observed in other direct reprogramming efforts. For example,
Ieda et al. detected alphaMHC-GFP+ cardiomyocytes after
only three days of reprogramming from fibroblasts (Ieda et al.,
2010). Together with these other studies, the results confirm
the power of using key developmental transcription factors for
direct reprogramming of various cell types (Huang et al., 2011;
Ieda et al., 2010; Vierbuchen et al., 2010; Xie et al., 2004).
It is evident that the cells obtainedwith the current protocol
were not mature, fully functioning β-cells after 96 h. Firstly,
the expression of both Ins1 and Ins2 mRNA was at a reduced
level compared to that seen in pancreatic islets. Secondly,
rGBCs were not responsive to glucose stimulation, a common
problem for artificially generated β-cells (Kubo et al., 2011;
Nostro et al., 2011). Thirdly, the RNA-Seq data showed many
genes that were either under-expressed or over-expressed
compared to mature adult β-cells. Fourthly, rGBCs were
polyhormonal, another common characteristic of in vitro
reprogrammed cells (D'Amour et al., 2006; Nostro et al.,
2011). Finally, rGBCs were unable to reverse the hyperglycemic
state of diabetic mice after transplantation. However, it is
possible that the engrafted cells were simply too few in
numbers to have a substantial effect on blood glucose levels. In
fact, insulin-positive cells could be detected in the grafts
of transplanted mice. Alternatively, some form of in vivo
maturation may be required for generation of functioning
β-cells, as has been shown to be needed for the transplantation
of ESC-derived β-cells into diabetic mice (Kroon et al., 2008).
Further studies are required to investigate the in vivo
maturation of transplanted rGBCs.
A common phenotype ofmost in vitro-derivedβ-like cells is
the absence of GSIS (Kubo et al., 2011; Nostro et al., 2011).
Similar to these studies, we could not reprogram GBCs to
acquire GSIS, an essential feature of typical pancreatic
β-cells. In the future, therefore, it will be imperative to
determine the missing factor(s) required to instigate glucose
sensing, insulin packaging and insulin secretion. The compar-
ison of rGBCs to β-cells from type 2 diabetic patients may be
appropriate. Type 2 diabetic patients exhibit defective insulin
secretion, exemplified by the loss of GSIS. We analyzed the
expression of known genes that when mutated can result in
loss of insulin secretion. One factor that was under-expressed
in rGBCs relative to β-cells was transmembrane protein 27,
encoded by Tmem27. Also known as Collectrin, this factor
controls insulin exocytosis and has been implicated as a key
component of glucose-stimulated insulin secretion (Fukui
et al., 2005). Decreased Tmem27 gene expression has also
been detected in islets from type 2 diabetic patients (Altirriba
et al., 2010). Other genes that were not expressed at
comparable levels to actual β-cells were Slc30a8 and Nnat
that are involved in vesicle maturation and insulin secretion
respectively (Artner et al., 2010). Future reprogramming
studies should be aimed at the induction of these genes that
are essential for mature β-cell function.
In conclusion, the data presented here support a novel
strategy to generate pancreatic β-like cells. The gall bladder is
a readily accessible and non-essential tissue that contains
cells amenable to large-scale expansion and reprogramming
to a pancreatic fate. In addition, our data indicate that this
endodermal derivative is more amenable to reprogramming
than skin fibroblasts. However, the reprogramming is currently
only partial and the rGBCs did not become fully functional,
514 R.D. Hickey et al.mature β-cells in vitro. Although there were many up-
regulated marker genes detected in rGBCs, global RNA-Seq
analysis was needed to properly characterize the cells relative
to true functional β-cells, something that is commonly missing
in other reprogramming studies. Nonetheless, the results
outlined here will be useful for further experiments aimed at
generating a direct differentiation-based cell therapy for type 1
diabetes in human patients.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.02.005.
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